Ethinyl Estradiol And Norethindrone

Introduction Overview

Generic Name

ethinyl estradiol and norethindrone

Brand Name

Jinteli

Dosage Form

Oral tablet

Drug Class

Sex hormone combinations

Pharmacokinetics

Absorption:
Ethinyl estradiol and norethindrone, administered orally in combination as Jinteli, exhibit rapid absorption primarily from the gastrointestinal tract. Ethinyl estradiol is well absorbed but undergoes significant first-pass metabolism in the liver, which can reduce systemic bioavailability. The extent of absorption can be influenced by formulations and concurrent intake of foods such as grapefruit juice, which inhibits cytochrome P450 enzymes affecting ethinyl estradiol levels. Norethindrone is also readily absorbed orally, achieving peak plasma concentrations typically within 1 to 2 hours. The oral bioavailability for norethindrone is approximately 65-85%, with some variability due to first-pass hepatic metabolism.

Distribution:
After absorption, both ethinyl estradiol and norethindrone are extensively bound to plasma proteins, predominantly albumin, with ethinyl estradiol also binding to sex hormone-binding globulin (SHBG). The volume of distribution for these hormones is moderate, reflecting distribution mostly in highly perfused tissues including reproductive organs. Ethinyl estradiol achieves steady-state concentrations after several days of dosing. The drugs exhibit placental transfer, and both cross the blood-brain barrier to a limited extent. Their distribution is influenced by protein-binding dynamics and metabolic enzyme activity.

Metabolism:
Ethinyl estradiol undergoes extensive hepatic metabolism via cytochrome P450 enzymes, particularly CYP3A4, leading to various hydroxylated metabolites which are further conjugated. Norethindrone metabolism occurs through reduction and conjugation, also mediated in part by CYP3A4 pathways. The combination formulation can influence metabolic clearance rates, and co-administered drugs inducing or inhibiting CYP450 enzymes (e.g., rifampin, anticonvulsants) can alter plasma hormone levels, potentially reducing contraceptive efficacy.

Elimination:
The elimination half-life of ethinyl estradiol ranges approximately between 12 to 36 hours, whereas norethindrone has an elimination half-life of roughly 5 to 14 hours. Both hormones are excreted primarily via urine and feces as conjugated metabolites, with negligible amounts of unchanged drug detected. The drug undergoes enterohepatic recirculation, which prolongs the effective presence of ethinyl estradiol. Renal or hepatic impairment can alter elimination kinetics, highlighting the necessity for careful monitoring.

Dosage Forms

Available Dosage Forms:
Jinteli is provided as oral tablets in blister packs integrated with Dialpak® tablet dispensers containing 28 tablets per pack. The tablets are of the standard oral contraceptive formulation containing combined doses of ethinyl estradiol and norethindrone. While exact milligram strengths for Jinteli tablets are not explicitly provided in the sourced data, shared formulations under similar brand names typically feature low-dose ethinyl estradiol (20-35 mcg) combined with norethindrone (0.5-1 mg), consistent with common combined oral contraceptives.

Dosages for Adults and Adolescents:
For contraception, the standard dosing regimen involves taking one active tablet daily for 21 consecutive days at the same time each day, followed by either a 7-day tablet-free interval or a 7-day interval with inert (placebo) tablets depending on the specific product formulation (e.g., Loestrin® 21 or Loestrin® Fe variants). This cycle is repeated monthly. Adolescents who have commenced menstruation may use the same regimen under physician guidance. Initiation can occur on either the first day of the menstrual cycle (Day 1 start) or the first Sunday after menstruation begins (Sunday start), with emphasis on strict adherence to dosing schedules.

Specific Patient Populations:
Use in pediatric populations (pre-menarche) is not advised; however, safety and efficacy data support use in adolescent females after menarche. No geriatric dosing is applicable. Use during breastfeeding is generally not recommended due to unknown effects on infants; benefits and risks should be weighed carefully by clinicians. Dose adjustments are rarely necessary but monitoring is crucial in patients with hepatic impairment, coagulation disorders, or those taking concurrent medications influencing hepatic enzymes.

Clinicians should counsel patients regarding missed doses, emphasizing prompt replacement of missed active pills and use of supplemental contraceptive methods as per established protocols.

Mechanism Of Action

Jinteli combines two synthetic hormones, ethinyl estradiol and norethindrone, functioning synergistically as a combined oral contraceptive. The principal mechanism centers around suppression of ovulation. Ethinyl estradiol, a potent estrogen analog, exerts negative feedback on the hypothalamic-pituitary axis, inhibiting the secretion of follicle-stimulating hormone (FSH). Concurrently, norethindrone, a progestin, suppresses luteinizing hormone (LH) surge essential for ovulation. This combined suppression prevents follicular maturation and release of an oocyte.

Additionally, norethindrone induces alterations in the cervix by thickening cervical mucus, creating a hostile environment that hinders sperm penetration and migration into the uterine cavity. It also induces changes in the endometrium, making it less receptive to implantation in the event fertilization occurs. Ethinyl estradiol stabilizes the endometrial lining, reducing breakthrough bleeding, thereby enhancing cycle control.

At the molecular level, ethinyl estradiol binds estrogen receptors (ERα and ERβ) to modulate gene transcription influencing reproductive tissue differentiation, while norethindrone interacts with progesterone receptors to regulate gene expression tied to ovulatory cycles. Both agents modulate signaling pathways involved in the hypothalamic-pituitary-gonadal axis.

Clinical studies reveal this dual-hormone mechanism markedly reduces the risk of pregnancy when adherence is optimal. Comparative mechanisms with other contraceptives such as progestin-only pills highlight Jinteli's advantage in improved cycle control and decreased incidence of breakthrough bleeding. Research also indicates the ethinyl estradiol component can impact hepatic production of clotting factors and lipid metabolism, underscoring the importance of patient selection and monitoring during therapy.

Pharmacological Actions

Combined estrogen and progestin activity regulating female reproductive physiology.
Suppression of ovulation via hypothalamic-pituitary-gonadal axis inhibition.
Thickening of cervical mucus impeding sperm motility.
Endometrial alteration reducing likelihood of implantation.
Modulation of menstrual cycle characteristics to reduce breakthrough bleeding.
Stabilization of hormonal fluctuations contributing to cycle regularity.
Estrogen receptor-mediated gene transcription affecting reproductive tissues.
Progestin receptor-mediated regulation of ovulation and uterine environment.
Secondary effects on lipid metabolism and hepatic protein synthesis.
Prevention of follicular development through FSH suppression.
Inhibition of LH surge to prevent follicle rupture and ovulation.
Reduction in risk of pregnancy with proper adherence and dosing schedule.
Minimal androgenic activity compared to some other progestins.
Influence on endocervical glycogen affecting spermatozoa survival.
Interaction with clotting factor synthesis pathways relevant to thromboembolic risk.

Therapeutic Or Clinical Uses

Primary prevention of pregnancy via combined oral contraception.
Regulation of menstrual cycles in women requiring hormonal birth control.
Management of menstrual-related symptoms such as dysmenorrhea.
Contraceptive option for adolescents post-menarche and adult women.
Use as part of hormone replacement therapy regimens where combined estrogen-progestin is indicated.
Reduction of ovarian cyst formation in some patients through ovulation suppression.
Adjunctive treatment in endometriosis symptom management (off-label).
Modification of menstrual bleeding patterns in women with irregular cycles.
Potential non-contraceptive benefits including decreased risk of certain ovarian and endometrial cancers.
Improvement in acne in some patients due to hormonal regulation.
Management of anemia secondary to menstrual blood loss through cycle control.
Reduction in incidence of functional ovarian cysts.
Alternative to permanent sterilization for women seeking reversible contraception.
Treatment consideration in cases where non-hormonal contraceptives are contraindicated.
Contraceptive choice in women without contraindications to estrogen-containing therapies.

Side Or Adverse Effects

Nausea and vomiting, especially during initial months of therapy.
Irregular vaginal bleeding including spotting and breakthrough bleeding.
Breast tenderness or enlargement.
Headache, including migraine exacerbation.
Increased risk of thromboembolism (deep vein thrombosis, pulmonary embolism).
Changes in mood such as anxiety, irritability, or depression.
Weight changes and fluid retention leading to edema.
Skin changes including rash, erythema, or pigmentation alterations.
Visual disturbances including blurred vision or changes when wearing contact lenses.
Elevated blood pressure in some patients.
Gastrointestinal disturbances such as diarrhea or constipation.
Dizziness or lightheadedness potentially due to blood pressure changes.
Rare hypersensitivity reactions including hives, swelling, and anaphylaxis.
Gallbladder disease exacerbation or development.
Potential increased risk of breast or reproductive organ cancers with prolonged use.

Precautions

Regular medical monitoring including blood pressure and physical examinations.
Avoid use in women over 35 years of age who smoke due to increased cardiovascular risk.
Assess for history of thromboembolic disorders prior to initiation.
Use with caution in patients with hypertension or uncontrolled diabetes.
Discontinue use if significant liver dysfunction or jaundice develops.
Monitor patients with migraine, particularly with aura, due to stroke risk.
Avoid concomitant use with certain hepatitis C medications (e.g., paritaprevir/ritonavir).
Patient education regarding strict adherence to dosing schedule to maintain efficacy.
Counsel regarding possible interactions with various medications and supplements.
Evaluate breast health prior to and during use given possible cancer risks.
Advise patients about risk of breakthrough bleeding and conditions necessitating medical consultation.
Review potential for gallbladder disease prior to initiation.
Encourage smoking cessation to reduce cardiovascular risk.
Discuss weight management and lipid control as part of comprehensive care.
Ensure understanding of missed dose management to prevent unintended pregnancy.

Warnings

Smoking combined with use in women over 35 significantly increases risk of serious cardiovascular events including heart attack and stroke.
Risk of thromboembolic events such as deep vein thrombosis and pulmonary embolism elevated during use.
May increase risk of breast and reproductive system cancers with prolonged use.
Potential for serious liver problems evidenced by jaundice, dark urine, or pale stools.
Not protective against HIV infection or other sexually transmitted diseases.
Use contraindicated in patients with known or suspected estrogen-dependent neoplasia.
Serious allergic reactions, though rare, require immediate medical attention.
Should not be used concomitantly with certain antiviral agents due to decreased efficacy or increased toxicity.
Avoid use in patients with uncontrolled hypertension or active liver disease.
May exacerbate conditions such as epilepsy, migraine, or gallbladder disease.
Use with caution in patients with a history of depression or mood disorders.
Discontinue prior to major surgery to reduce thromboembolic risk as advised by physician.
Close monitoring required in presence of risk factors such as obesity and hyperlipidemia.
Possible interaction with numerous drugs necessitating thorough medication reconciliation.
Periodic evaluation recommended to assess ongoing suitability of therapy.

Contraindication

Women over 35 years who smoke due to elevated cardiovascular risks.
History or presence of thromboembolic disorders including deep vein thrombosis or pulmonary embolism.
Known or suspected breast cancer or other estrogen-dependent malignancies.
Severe or uncontrolled hypertension not adequately managed.
Active liver disease or liver tumor.
Undiagnosed abnormal vaginal bleeding of unknown origin.
Known hypersensitivity to ethinyl estradiol, norethindrone, or any components of the formulation.
During pregnancy or suspected pregnancy due to potential fetal harm.
History of or current cerebrovascular disease including stroke or transient ischemic attack.
Combination use with hepatitis C virus medications such as ombitasvir/paritaprevir/ritonavir and dasabuvir.
Migraine with aura because of increased risk of stroke.
Patients with cholestatic jaundice related to previous hormonal contraceptive use.
Presence of estrogen-dependent neoplasms or tumors.
Severe diabetes with vascular involvement or retinopathy.
Thrombogenic valvular or thrombophilic disorders.

Drug Interactions

Contraindicated with hepatitis C virus treatment agents such as dasabuvir, ombitasvir, paritaprevir, ritonavir, and tranexamic acid.
Decreased contraceptive efficacy when co-administered with hepatic enzyme inducers including carbamazepine, phenobarbital, phenytoin, and rifampin.
Potential increased risk of side effects or altered levels when used with antibiotics like amoxicillin and doxycycline.
Interactions with antiretrovirals (indinavir, lopinavir, nelfinavir) may affect hormone levels.
Caution with use of benzodiazepines (diazepam, lorazepam) and anticonvulsants (lamotrigine) due to altered metabolism.
May potentiate side effects of warfarin and other anticoagulants.
Concomitant use with St. John's Wort reduces contraceptive effectiveness via CYP3A4 induction.
Interaction with corticosteroids such as dexamethasone may affect hormone action and metabolism.
Drugs such as bupropion and cimetidine may alter progestin or estrogen levels.
Alcohol and tobacco use can exacerbate cardiovascular risks and alter drug metabolism.
Potential increased risk of serotonin syndrome with co-administration of some antidepressants.
Some drugs like atazanavir and ritonavir significantly influence hormonal levels by enzyme inhibition.
Reduced effectiveness when administered with certain antibiotics and antifungals.
Interactions with lipid-lowering agents such as atorvastatin require monitoring.
Careful management needed when combined with immunosuppressants like cyclosporine.

Preparations Of The Drug

Oral tablet formulation containing combined ethinyl estradiol and norethindrone in varying strengths.
Packaged in blister packs with Dialpak® dispensers for ease of daily dosing and compliance.
Available in combination birth control formulations similar to Loestrin®, Microgestin®, and Junel® products.
Dosage strengths typically feature low-dose ethinyl estradiol (20-35 mcg) paired with norethindrone doses around 0.5-1 mg.
Includes active and inert (placebo) tablets to maintain a consistent 28-day regimen.
Manufactured with quality controls to ensure hormone stability and precise dosing.
Provided with patient instructions detailing schedule adherence, missed dose management, and storage requirements.
Manufactured under regulatory guidelines ensuring safety for contraceptive use.
No parenteral or alternative routes other than oral tablets currently marketed under Jinteli brand.
Packaging designed to minimize exposure to moisture, heat, and light to preserve drug integrity.
Supplemental materials provided to educate on drug use, risks, and side effects.
Intended for prescription-only distribution with clinician oversight.
Not formulated for emergency contraception use.
Not currently packaged in chewable or liquid forms under this brand name.
Stored at room temperature, protected from freezing, and out of reach of children.